Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oncimmune Ltd.

www.oncimmune.co.uk

Latest From Oncimmune Ltd.

Device Debut: Oncimmune Pushes Liver Cancer Test In The US

Oncimmune has expanded its offering in the US with the launch of a blood-based liver cancer test, the second product to emerge from its EarlyCDT platform.

Approvals Research & Development

Market Intel: Liquid Biopsies For Cancer Screening – Far From Reach Or Close At Hand?

While liquid biopsy is becoming routine for cancer treatment stratification and monitoring, using blood tests to screen for early cancer in asymptomatic people remains a tantalizing target. Some question how practical such a test could be but several companies are already en route - some further down the road than others - to achieve this goal. Illumina spin-out Grail is one of these companies and while it is not alone, in a field where size matters, it may have an advantage. This article delves deeper into how these different technologies work and when they could reach the market.

In Vitro Diagnostics Cancer

Oncimmune Reels In New Strategy Head And More Capital

Oncimmune, the UK specialist in autoantibody-based tests for early cancer detection, has bullked up its human and financial resources with the appointment of a chief medical and strategy officer, and the closing of an investment tranche from its Chinese partner.

In Vitro Diagnostics Cancer

Oncimmune Kicks Off 2018 With China Pact For Lung Cancer Test

Oncimmune's commercialization of its early cancer diagnostic technology continues to gather pace as the firm enlists yet another distribution partner in Asia. The exclusive deal is for China, where the market opportunity for the company's EarlyCDT-Lung test is sizeable. The agreement also includes an equity investment by the Chinese partner in Oncimmune.

Cancer In Vitro Diagnostics
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
    • Chemistry, Immunoassay
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Oncimmune Ltd.
  • Senior Management
  • Adam Hill, PhD, CEO
    Matthew Hall, CFO
  • Contact Info
  • Oncimmune Ltd.
    Phone: 115 8231869
    Clinical Sciences Bldg. Nottingham Hosp.
    Hucknall Hall
    Nottingham, NG5 1PB
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register